Compare Equinor ASA (EQNR) vs Recursion Pharmaceuticals Inc (RXRX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Equinor ASA vs Recursion Pharmaceuticals Inc — how do they compare? Equinor ASA trades at $35.77 (market cap $82.75B), while Recursion Pharmaceuticals Inc trades at $3.15 (market cap $1.75B). The key difference: Equinor ASA is far larger — about 47.3× Recursion Pharmaceuticals Inc's market cap, and Equinor ASA pays a 4.24% dividend while Recursion Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| EQNR | RXRX | |
|---|---|---|
Market Cap | $82.75B | $1.75B |
Sector | Energy | Health |
52-Week High | $42.40 | $6.79 |
52-Week Low | $22.41 | $2.84 |
Enterprise Value | $94.51B | $1.17B |
Dividend Yield | 4.24% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
EQNR trades at $36.19, up 0.36% on the day, with a bullish technical signal from moving averages. Recent earnings show mixed results, with a Q1 2026 beat but a Q3 2025 miss. The company maintains a strong balance sheet with $21.24B in cash and a low EV/EBITDA of 2.39. Recent news highlights strategic investments in subsea projects and a share buy-back program, reinforcing growth commitments.
The outlook is cautiously optimistic, supported by low valuation metrics and strategic asset expansions. Key risks include volatile energy prices and declining net income margins. Analyst sentiment is mixed, with a 30.43% buy rating, suggesting potential upside but requiring monitoring of execution on production targets.
Recursion Pharmaceuticals (RXRX) trades at $3.175, down 4.94% on the day, reflecting ongoing investor concerns about profitability. The stock shows bearish technical signals with negative moving averages, while fundamentals reveal significant losses with a net income margin of -851.51% despite recent earnings beats. Analyst consensus is mixed with 40% buy ratings but a $7.83 price target suggesting substantial upside potential from current levels.
The outlook remains speculative given the company's heavy losses and cash burn, though AI-driven drug discovery platform and recent clinical progress offer long-term potential. Key risks include prolonged unprofitability, intense biotech competition, and dependence on successful drug development. The stock presents high-risk/high-reward characteristics suitable only for risk-tolerant investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Equinor ASA
Equinor is a Norway-based integrated oil and gas company. It has been publicly listed since 2001, but the government retains a 67% stake. Operating primarily on the Norwegian Continental Shelf, the firm produced 2.1 million barrels of oil equivalent per day in 2021 (52% oil) and ended the year with 5.4 billion barrels of proven reserves (49% oil). Operations also include offshore wind, solar, oil refineries and natural gas processing, marketing, and trading.
Read more on EQNR →About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →
